Health Care

UnitedHealth Group Reports 2023 Results

UnitedHealth Group Reports 2023 Results — Revenues of $371.6 Billion Grew 15% Year-Over-Year — Earnings from Operations Grew 14% — Cash Flows from Operations were $29.1 Billion or 1.3x Net Income — Full Year and Fourth Quarter Net Earnings were $23.86 and $5.83 Per Share — Full Year and Fourth Quarter Adjusted Net Earnings were $25.12 and $6.16 Per Share UnitedHealth Group (NYSE: UNH) reported full year and fourth quarter 2023 results reflecting broad-based growth at Optum and UnitedHealthcare. This press release features multimedia. View the full release here: UnitedHealth Group corporate headquarters (Photo: Business Wire) “UnitedHealth Group enters 2024 well prepared to build on our efforts to improve patient care and consumer experiences broadly, and to continue delivering strong and balanced growth,” said Andrew Witty, chief executive officer of UnitedHealth Group. UnitedHealth Group affirmed the 2024 performance objectives established at its November 29(th) Investor Conference, excluding the potential impacts […]

UnitedHealth Group Reports 2023 Results Read Post »

UnitedHealth Group Incorporated (UNH) Q4 2023 Earnings Call Transcript Summary

The following is a summary of the UnitedHealth Group Incorporated (UNH) Q4 2023 Earnings Call Transcript: Financial Performance: UnitedHealth reported 2023 revenue of $372 billion, a growth of over 14% with double-digit growth achieved by both Optum and UnitedHealthcare. Fourth quarter adjusted earnings per share of $6.16 grew 15%, leading to a 13% growth in the full-year adjusted earnings per share, which reached $25.12. Due to the sale of Brazil operations, the company expects to record a charge of approximately $7 billion, primarily stemming from non-cash foreign currency translation losses. The cash flow from operations in 2023 reached $29 billion or 1.3 times the net income. The company returned nearly $15 billion to shareholders through share repurchase and dividends and set aside over $10 billion in growth capital for future development. Business Progress: UnitedHealth added 900,000 new members to value-based care arrangements, bringing the total count to over 4.1 million.

UnitedHealth Group Incorporated (UNH) Q4 2023 Earnings Call Transcript Summary Read Post »

Earnings Outlook For UnitedHealth Group

UnitedHealth Group (NYSE:UNH) is set to give its latest quarterly earnings report on Friday, 2024-01-12. Here’s what investors need to know before the announcement. Analysts estimate that UnitedHealth Group will report an earnings per share (EPS) of $5.98. UnitedHealth Group bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Earnings Outlook For UnitedHealth Group Read Post »

Eli Lilly’s Fiscal 2024 Revenue Guidance May Top Views As New Obesity Drug Gains Steam, Morgan Stanley Says

Eli Lilly and Company’s (LLY) fiscal 2024 revenue guidance may tilt higher than expected on the momentum of its new weight loss drug while its earnings forecast may come in short amid multiple ongoing late-stage trials, Morgan Stanley said Thursday. The brokerage increased its price target to $763 from $727 and reiterated an overweight rating on the stock ahead of financial results due Feb. 6. Eli Lilly is expected to report fiscal 2023 figures and provide initial guidance for the new year. The brokerage sees 6% upside to consensus revenue estimates for 2024 on a “solid launch” of Eli Lilly’s weight loss drug Zepbound in the US, which it said is tracking ahead of the company’s blood-sugar regulation drug Mounjaro at a similar time point. The Capital IQ consensus is for fiscal 2024 revenue of $38.92 billion. In 2024, Morgan Stanley now estimates Zepbound revenue of $6.1 billion, above the

Eli Lilly’s Fiscal 2024 Revenue Guidance May Top Views As New Obesity Drug Gains Steam, Morgan Stanley Says Read Post »

UnitedHealth Reports Earnings Friday. Here’s What to Expect. — Barrons.com

By Josh Nathan-Kazis The managed care giant UnitedHealth Group kicks off the earnings season for healthcare companies Friday morning. Investors will watch closely for updates on how intensely patients used healthcare services in the last quarter of the year, a key bellwether for the healthcare sector. Higher-than-expected utilization of medical services by patients enrolled in Medicare Advantage plans over the past year has periodically sparked worries among investors in recent months. UnitedHealth’s medical loss ratio for the fourth quarter, or MLR — which tracks the proportion of premiums paid out to cover medical expenses — will be closely watched. A higher MLR means more spending on medical expenses, and less room for profit. Analysts expect UnitedHealth to report an MLR of 84.1% for the fourth quarter, according to FactSet, higher than the 82.8% paid out in the same quarter in 2022. Nevertheless, Wall Street projects UnitedHealth will report earnings of

UnitedHealth Reports Earnings Friday. Here’s What to Expect. — Barrons.com Read Post »

Intuitive Surgical Still Seeing Deceleration of Weight-Loss Surgeries

Intuitive Surgical is still grappling with a slowdown in demand for bariatric surgeries due to the rise of GLP-1 medications like Ozempic, Chief Executive Gary Guthart tells an audience at the JPMorgan Healthcare Conference. “The deceleration hasn’t stopped,” he says. “We’re still growing, but it’s decelerating.” What that means for the longterm outlook for bariatric weight-loss surgeries is unclear. Company executives have previously said they expect the GLP-1-related slowdown to only be short term. Shares rise 10%.

Intuitive Surgical Still Seeing Deceleration of Weight-Loss Surgeries Read Post »

Intuitive Surgical Announces Preliminary Fourth Quarter and Full Year 2023 Results

Intuitive Surgical Announces Preliminary Fourth Quarter and Full Year 2023 Results SUNNYVALE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) — Intuitive Surgical (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced certain unaudited preliminary fourth quarter and full year 2023 financial results ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. Financial and Operational Highlights — Fourth quarter 2023 worldwide da Vinci procedures grew approximately 21% compared with the fourth quarter of 2022. The comparative fourth quarter of 2022 reflected a resurgence of COVID-19 in China, which negatively impacted procedure volumes in the region. — Full year 2023 worldwide da Vinci procedures grew approximately 22% compared with 2022. The Company expects worldwide da Vinci procedures to increase approximately 13% to 16% in 2024 as compared to 2023. — The Company placed 415 da

Intuitive Surgical Announces Preliminary Fourth Quarter and Full Year 2023 Results Read Post »

Intuitive Surgical Expects Q4 Revenue to Rise

Intuitive Surgical (ISRG) said late Tuesday it expects Q4 revenue of about $1.93 billion, up 17% compared with $1.66 billion a year earlier. Analysts polled by Capital IQ expect $1.88 billion. The company said it expects 2023 revenue of about $7.12 billion, up 14% compared with $6.22 billion a year earlier. Analysts surveyed by Capital IQ expect $7.07 billion.

Intuitive Surgical Expects Q4 Revenue to Rise Read Post »

Pfizer (NYSE:PFE) Stock Analyst Ratings

Pfizer (NYSE:PFE) Stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/09/2024 51.52% Cantor Fitzgerald → $45 Reiterates Overweight → Overweight 01/04/2024 7.74% TD Cowen → $32 Downgrades Outperform → Market Perform 12/14/2023 21.21% Truist Securities $42 → $36 Maintains Buy 12/14/2023 -9.09% UBS $34 → $27 Maintains Neutral 12/14/2023 -5.72% Barclays $34 → $28 Maintains Equal-Weight 12/04/2023 41.41% Truist Securities → $42 Reiterates Buy → Buy 11/20/2023 152.53% Cantor Fitzgerald → $75 Reiterates Overweight → Overweight 11/01/2023 14.48% Barclays $35 → $34 Maintains Equal-Weight 11/01/2023 24.58% Morgan Stanley $39 → $37 Maintains Equal-Weight 10/20/2023 14.48% UBS $36 → $34 Assumes Neutral → Neutral 10/17/2023 41.41% Truist Securities $62 → $42 Maintains Buy 10/17/2023 31.31% Morgan Stanley $40 → $39 Maintains Equal-Weight 10/17/2023 17.85% Wells Fargo $39 → $35 Maintains Equal-Weight 10/16/2023 11.11% BMO Capital $44 → $33 Maintains Outperform 10/16/2023 17.85% Citigroup

Pfizer (NYSE:PFE) Stock Analyst Ratings Read Post »

Intuitive Surgical (NASDAQ:ISRG) stock Analyst Ratings

Intuitive Surgical (NASDAQ:ISRG) stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/03/2024 15.64% Raymond James $310 → $372 Maintains Outperform 12/22/2023 21.24% Truist Securities $375 → $390 Maintains Buy 12/12/2023 16.58% Truist Securities $320 → $375 Maintains Buy 12/04/2023 2.59% Morgan Stanley $300 → $330 Maintains Equal-Weight 11/17/2023 8.81% Stifel $315 → $350 Maintains Buy 11/17/2023 -1.14% HSBC → $318 Initiates Coverage On → Buy 10/23/2023 -6.74% Morgan Stanley $330 → $300 Maintains Equal-Weight 10/20/2023 1.03% Piper Sandler $385 → $325 Maintains Overweight 10/20/2023 10.36% RBC Capital → $355 Reiterates Outperform → Outperform 10/20/2023 21.24% Citigroup $400 → $390 Maintains Buy 10/20/2023 12.85% Wells Fargo $386 → $363 Maintains Overweight 10/20/2023 -3.63% Raymond James $368 → $310 Maintains Outperform 10/16/2023 6.32% Leerink Partners → $342 Initiates Coverage On → Outperform 08/17/2023 11.91% RBC Capital → $360 Reiterates Outperform → Outperform 07/24/2023 2.59%

Intuitive Surgical (NASDAQ:ISRG) stock Analyst Ratings Read Post »

Scroll to Top